Werewolf Therapeutics, Inc. HOWL 深 沪
等待开盘 08-25 09:30:00 美东时间
0.8845
+0.011
+1.26%
华盛通- 最 高0.90
- 今 开0.85
- 成交量 1030.09万股
- 最 低 0.811
- 昨 收 0.8735
- 总市值 4298.59万
- 52周最高 2.38
- 市盈率 静 --
- 换手率 21.20%
- 52周最低 0.27
- 委 比 -71.43%
- 总股本 4859.91万
- 历史最高 23.99
- 量 比 0.19
- 振 幅 10.19%
- 历史最低 0.27
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OSI Systems (OSIS) Stock Drops 13% After Hours: Here’s What’s Going On?
OSI Systems, Inc. (NASDAQ:OSIS) shares fell 13.41% in after-hours trading Thursday after the company reported fiscal 2026 results and announced an expansion of its stock repurchase authorization. The stock closed Thursday’s regular session down 1.28% at $218.09. It fell 13.41% to $188.84 in after-ho...
08-21 13:15
Werewolf Therapeutics shares are trading higher after the company announced the sale of its pre-clinical INDUCER platform and its INDUKINE platform to EMD Serono Research & Development Institute.
Werewolf Therapeutics shares are trading higher after the company announced the sale of its pre-clinical INDUCER platform and its INDUKINE platform to EMD Serono Research & Development Institute.
08-21 04:30
Werewolf Therapeutics shares are trading lower after the company reported Q2 financial results. Weakness may have stemmed from cash pressure, reliance on one‑time revenue from Jazz asset sale, and uncertainty around management’s strategic review.
Werewolf Therapeutics shares are trading lower after the company reported Q2 financial results. Weakness may have stemmed from cash pressure, reliance on one‑time revenue from Jazz asset sale, and uncertainty around management’s strategic review.
08-01 03:37
Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.29) by 127.59 percent. This is a 120 percent increase over losses of $(0.40) per share from the same period last year. The company reported $21.000 million in sales thi...
07-31 19:27
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Werewolf Therapeutics reported Q2 2026 results, including a $21M payment from asset transactions, enabling continued development of its INDUKINE and INDUCER platforms. Cash decreased to $22M, with collaboration revenue of $21M and net income of $3.7M. The company plans to update on strategic alternatives and clinical trials in H2 2026.
07-31 11:00
Why e.l.f. Beauty Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Shares of elf Beauty Inc (NYSE: ELF) rose sharply in pre-market trading after beating analyst expectations with fourth-quarter earnings of 32 cents per share and revenue of $449.29 million, up 35%. Other pre-market gainers include WHLR, ATPC, LIMN, JUNS, ILLR, NCPL, VIDA, WNW, and APLD. The biggest losers are WGRX, MMA, IPW, and CAPS.
05-21 17:21
Werewolf Therapeutics Q1 EPS $(0.28), Inline
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 30 percent increase over losses of $(0.40) per share from the same period last year.
05-08 04:45
Earnings Scheduled For March 27, 2026
Companies Reporting Before The Bell • Instil Bio (NASDAQ:TIL) is expected to re...
03-27 19:11
Werewolf Therapeutics Q4 EPS $(0.20) Beats $(0.35) Estimate
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.35) by 43.18 percent. This is a 56.52 percent increase over losses of $(0.46) per share
03-27 19:02
